Updated 12:17 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 58,232.43 -0.96%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $58,232 −0.96% VIX 35.89 +26.20% latest tape · as of 12:17 UTC
The Screen · Healthcare · Biotechnology

Inhibrx Biosciences, Inc. logoInhibrx Biosciences, Inc.

INBX · Nasdaq · USD · Market cap $1.1B · 109 employees

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.

FAIL · Does not pass the screen
68.97 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price68.97 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.94x the price, above our 2.00x limit.
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans slightly to calls (put/call 0.73)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Markup ?
Screened · screened 2026-11-20
  • Trend Markup
  • Insiders insiders bought, latest filing 2026-10-14
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.73, read 2026-11-15
  • Ethical does not pass the values gate
Price68.97 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-12Read Markup90.59-23.9% to today Distribution gives way to Markup after a 26% rise in 11 days
2026-11-01Read Distribution71.78-3.9% to today ✓Markdown gives way to Distribution after a 36% slide in 4 weeks
2026-10-02Read Markdown112.04-38.4% to today ✓Markup gives way to Markdown after a 10% slide in 4 weeks
2026-09-02Read Markup123.93-44.3% to today Distribution gives way to Markup after a 34% rise in 9 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Inhibrx Biosciences, Inc. holds its Markup at $68.97. Elevated stress, defensive posture warranted, held for 14 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateElevated stress, defensive posture warranted, held for 14 days
Price at the screen$68.97
ValuationN/A trailing · -8.47 forward price to earnings
Values screenFAIL · score 70.0
Beta4.04
The Workings

Five Screens: INBX's Results

FAIL. Debt ratio

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 73.06% Below 33% Fail
Interest-bearing cash 0.00% Below 33% Pass
Receivables 84.80% Below 49% Fail
Revenue purity 100.00% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Inhibrx Biosciences,'s business is in a permissible area, but its interest-bearing debt is about 73% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when INBX's ethical verdict changes

Today INBX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.94x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
220.00Street low 230.00Street average 325.00Street high 68.97Price

Street: 3 covering, consensus Strong Buy. Average target +233%.

Chart
The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-8.5x
EPS, trailing-8.88
EPS, forward-8.76
Profit margin0.0%currently unprofitable
FCF yield-7.40%
Current ratio7.58comfortably covers its short-term bills
Beta4.04much more volatile than the market
Short interest, float0.31%
52-week range57.30 - 155.29
Market cap$1.1B
Employees109

INBX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $69.06 -21.3% Entry 18
2026-11-13 Markup $87.75 -3.1% Entry 17
2026-11-12 Markup · changed $90.59 0.0% Entry 16

The framework has shifted from distribution to markup since the last review.

2026-11-11 Distribution $90.61 -1.2% Entry 15
2026-11-10 Distribution $91.74 +8.5% Entry 14
2026-11-09 Distribution $84.52 +0.0% Entry 13
2026-11-08 Distribution $84.52 +0.0% Entry 12
2026-11-07 Distribution $84.52 +5.3% Entry 11
2026-11-06 Distribution $80.28 +11.8% Entry 10

Earnings landed in this window.

2026-11-01 Distribution · changed $71.78 -26.1% Entry 9

The framework has shifted from markdown to distribution since the last review. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on INBX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in INBX's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · INBX
DateInsiderTitleTypeSharesValue
2026-10-14 Lappe Mark CEO P - Purchase 10,040 $848,977
2026-09-25 Lappe Mark CEO P - Purchase 10,000 $998,784
2026-09-16 Kayyem Jon Faiz Dir P - Purchase 5,000 $500,000

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $127.58 -30.0% · $700 -30.0%
2 months $75.27 +18.6% · $1,186 +18.6%
3 months $69.30 +28.8% · $1,288 +28.8%
6 months $82.21 +8.6% · $1,086 +8.6%
1 year $15.37 +480.9% · $5,809 +480.9%
2 years $16.59 +438.2% · $5,382 +438.2%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever INBX does next, these words stay.

Inhibrx Biosciences, Inc. · INBX · Markup · $68.97
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.